Please ensure Javascript is enabled for purposes of website accessibility

Why T2 Biosystems Stock Soared Today

By Joe Tenebruso - Feb 5, 2021 at 3:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The diagnostic test maker's panels could help to combat the spread of new coronavirus variants.

What happened 

Shares of T2 Biosystems (TTOO -5.82%) jumped on Friday after the healthcare diagnostics specialist said its testing panel could detect the new strain of the coronavirus first identified in Brazil. As of 3:35 p.m. EST, its stock price was up more than 30%. 

So what 

T2 Biosystems has now confirmed that its T2SARS-CoV-2 Panel can detect many different coronavirus strains, including the variants first identified in the U.K., South Africa, and Brazil. A recent evaluation of more than 42,000 genome sequences for the novel coronavirus showed that T2 Biosystems' panel should detect 99.99% of all currently identified SARS-CoV-2 viruses. 

"We continue to actively monitor new variants of the COVID-19 virus to confirm that our technology remains a useful and reliable diagnostic tool for the many healthcare systems and people that need it during this time," T2 Biosystems CEO John Sperzel said in a press release. 

A person is wearing safety gloves while inserting a swab into a test tube.

Image source: Getty Images.

The T2SARS-CoV-2 Panel has demonstrated clinical sensitivity -- essentially, the ability of the test to correctly identify the people who have the disease -- of 95%. Additionally, the panel has demonstrated specificity -- the ability of the test to correctly identify those who do not have the disease -- of 100%. Better still, test results can be obtained in less than two hours using nasal swab samples. 

Now what

It will be vital for healthcare workers to have the ability to accurately and reliably detect new mutations of the coronavirus if we are to ever bring about an end to the COVID-19 pandemic. T2 Biosystems could play a key role in this area.

However, it's important to note that competition is intensifying in the coronavirus diagnostic market, and T2 Biosystems' challengers include industry giants like Abbott Laboratories and Roche. There will likely be room for several diagnostic test suppliers in this massive market, but as a far smaller company, T2 Biosystems' stock is a riskier investment than those of its larger rivals.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

T2 Biosystems, Inc. Stock Quote
T2 Biosystems, Inc.
$0.21 (-5.82%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.